Implantable collamer lens with a central hole: three years of follow-up

Session Details

Session Title: Phakic IOLs

Session Date/Time: Sunday 23/09/2018 | 08:00-10:00

Paper Time: 08:28

Venue: Room A3, Podium 1

First Author: : L.Fernandez-Vega Cueto SPAIN

Co Author(s): :    C. Lisa   B. Alfonso-Bartolozzi   J. Alfonso              

Abstract Details

Purpose:

The aim of the present study was to assess the long-term predictability, stability, safety, and efficacy of the V4c Visian Implantable Collamer Lens (ICL) with central hole to correct moderate to high myopia over a 36-month period.

Setting:

Instituto Universitario Fernandez-Vega, Oviedo, Spain

Methods:

This retrospective study included 184 eyes of 92 patients (30 male, 62 female) who were evaluated during three-years after implantation of the V4c ICL. The refraction, uncorrected distance visual acuity, best-corrected distance visual acuity (CDVA), intraocular pressure (IOP), endothelial cell count (ECC), vault, and adverse effects were evaluated every 12 months during the whole follow-up. A repeated measures analysis of variance (rANOVA) was performed to reveal significant differences through the follow-up period

Results:

The lens sizes chosen for all patients were 12.6, 13.2, or 13.7 mm. The mean spherical equivalent dropped from -8.30±2.98D preoperatively to -0.37±0.47D at 36 months post-surgery, with 91.8% eyes being within ±1.00D of emmetropia. At 36-months, 78.8% of eyes had no change in the Snellen lines of CDVA, while 8.7% gained 1 line, and 6.5% gained 2 or more lines. Mean ECC was 2742±340 cells/mm2 before and 2663±366 cells/mm2 at 36-months post-surgery. Mean IOP reduced from 13.7±1.9 mmHg preoperatively to 12.8±1.7 at 36 months post-surgery. Mean vault varied from 409±196 µm at 12-months to 349±165 µm at 36-months.

Conclusions:

The visual and refractive outcomes were very good and highly stable throughout the follow-up period, showing that this ICL model is predictable, stable, safe, and effective to correct myopia at long-term.

Financial Disclosure:

-